Posterior Fossa Decompression Followed by Duraplasty with Arachnoid-Preserving Technique for Primary and Recurrent Adult Chiari Malformation Type-1.5: A Comparative Retrospective Study
Journal of Neurological Surgery Part A: Central European Neurosurgery · 01.11.2025 · 86 (06) · 562-573
DOI: 10.1055/a-2590-6183 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Neurological Surgery Part A: Central European Neurosurgery, erschienen am 01.11.2025. Verfasst von Hüseyin Doğu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Istanbul Atlas University, Medical Faculty Hospital, Bağcılar, Istanbul, Turkey. Hauptthemen laut MEDLINE: Arnold-Chiari Malformation, Decompression, Surgical, Dura Mater, Cranial Fossa, Posterior. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Most studies on Chiari malformation (CM) are focused on CM Type-1. A new subtype, CM Type-1.5, lacks sufficient research. This study aims to evaluate the long-term surgical outcomes of posterior fossa decompression followed by duraplasty with arachnoid-preserving (PFDD-AP) technique for primary and recurrent CM Type-1.5. The medical charts of patients treated surgically for CM at our institute between January 2011 and January 2022 were reviewed retrospectively. Adult patients consecutively treated for CM Type-1.5 were selected as the core sample for the current study. Group A included primary cases (i.e., patients who had not previously been surgically treated), and Group B included recurrent cases. The surgical outcomes were compared by evaluating clinical and radiological findings. Thirty-four CM Type-1.5 cases out of 202 CM cases met the study criteria. Twenty-three and 11 cases represented Group A and Group B, respectively. The female-to-male ratio was 2/1. In Group B, the preoperative herniated tonsil extension and the obex position were statistically significantly longer, and retroversion and retroflexion angles were statistically considerably smaller ([p = 0.024; Z = − 2.26]; [p = 0.023; Z = − 2.27]; [p = 0.031; Z = − 2.29]; and [p = 0.0002; Z = − 3.72], respectively). For the cases presented with syringomyelia (SM) in both groups (n = 20), total and partial regression were recorded postoperatively in 65% and 15% of cases, respectively. The satisfactory recovery or improvement rate in neurological symptoms was 94.1%. Total or partial SM regression occurred following PFDD-AP in most adult patients with CM Type-1.5 who presented with SM. The PFDD-AP approach offers better results with fewer complications and recurrence rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Neurosurgery, Istanbul Atlas University, Medical Faculty Hospital, Bağcılar, Istanbul, Turkey.
- Department of Neurosurgery, Üsküdar University, Medical Faculty, Üsküdar, Istanbul, Turkey.
ORCID-Profile: Hüseyin Doğu, Anas Abdallah, Hidayet Akdemir
Zitieren
APA
Doğu, H., Abdallah, A., & Akdemir, H. (2025). Posterior Fossa Decompression Followed by Duraplasty with Arachnoid-Preserving Technique for Primary and Recurrent Adult Chiari Malformation Type-1.5: A Comparative Retrospective Study. Journal of Neurological Surgery Part A: Central European Neurosurgery, 86(06), 562-573. https://doi.org/10.1055/a-2590-6183
Vancouver
Doğu H, Abdallah A, Akdemir H. Posterior Fossa Decompression Followed by Duraplasty with Arachnoid-Preserving Technique for Primary and Recurrent Adult Chiari Malformation Type-1.5: A Comparative Retrospective Study. Journal of Neurological Surgery Part A: Central European Neurosurgery. 2025;86(06):562-573. doi:10.1055/a-2590-6183
BibTeX
@article{Dou2025,
author = {Doğu, Hüseyin and Abdallah, Anas and Akdemir, Hidayet},
title = {Posterior Fossa Decompression Followed by Duraplasty with Arachnoid-Preserving Technique for Primary and Recurrent Adult Chiari Malformation Type-1.5: A Comparative Retrospective Study},
journal = {Journal of Neurological Surgery Part A: Central European Neurosurgery},
year = {2025},
volume = {86},
number = {06},
pages = {562--573},
doi = {10.1055/a-2590-6183}
}
EUVIMED